Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy
Abstract Background It is uncertain whether the combination of immunotherapy and radiotherapy can provide survival benefits for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods We retrospectively analyzed the impact of radiotherapy on the efficacy of immunotherapy and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02801-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137898318299136 |
|---|---|
| author | Yanshuang Cheng Juan Wang Ji Sun Yahua Zhong Qiuji Wu |
| author_facet | Yanshuang Cheng Juan Wang Ji Sun Yahua Zhong Qiuji Wu |
| author_sort | Yanshuang Cheng |
| collection | DOAJ |
| description | Abstract Background It is uncertain whether the combination of immunotherapy and radiotherapy can provide survival benefits for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods We retrospectively analyzed the impact of radiotherapy on the efficacy of immunotherapy and prognostic analysis in 113 patients with R/M HNSCC in our institution from 2018 to 2022. The Kaplan–Meier method was utilized for survival analysis, and Cox regression analysis was conducted to identify prognostic factors. Results The median follow-up time was 14.0 months. During immunotherapy, 37 patients received radiotherapy, targeting primary tumors, lymph nodes, metastasis in liver, lung, bone, and other sites. We found that the group receiving immunotherapy combined with radiotherapy had higher objective response rate (67.6% vs 39.5%, p = 0.009) and disease control rate (94.6% vs 61.8%, p = 0.001) than those without radiotherapy. The median progression-free survival (20.0 months vs 4.0 months, p = 0.00098) and overall survival (not reached vs 26.0 months, p = 0.006) were improved in patients receiving radiotherapy compared to those not. Conclusions The combination of immunotherapy and radiotherapy demonstrates improved clinical outcomes in R/M HNSCC. |
| format | Article |
| id | doaj-art-6e099cde93e5463d89b3a9ad4b8f6bc8 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-6e099cde93e5463d89b3a9ad4b8f6bc82025-08-20T02:30:42ZengSpringerDiscover Oncology2730-60112025-06-0116111410.1007/s12672-025-02801-yRadiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapyYanshuang Cheng0Juan Wang1Ji Sun2Yahua Zhong3Qiuji Wu4Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan UniversityDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan UniversityDepartment of Cardiology, The First Affiliated Hospital, Sun Yat‑sen UniversityDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan UniversityDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan UniversityAbstract Background It is uncertain whether the combination of immunotherapy and radiotherapy can provide survival benefits for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods We retrospectively analyzed the impact of radiotherapy on the efficacy of immunotherapy and prognostic analysis in 113 patients with R/M HNSCC in our institution from 2018 to 2022. The Kaplan–Meier method was utilized for survival analysis, and Cox regression analysis was conducted to identify prognostic factors. Results The median follow-up time was 14.0 months. During immunotherapy, 37 patients received radiotherapy, targeting primary tumors, lymph nodes, metastasis in liver, lung, bone, and other sites. We found that the group receiving immunotherapy combined with radiotherapy had higher objective response rate (67.6% vs 39.5%, p = 0.009) and disease control rate (94.6% vs 61.8%, p = 0.001) than those without radiotherapy. The median progression-free survival (20.0 months vs 4.0 months, p = 0.00098) and overall survival (not reached vs 26.0 months, p = 0.006) were improved in patients receiving radiotherapy compared to those not. Conclusions The combination of immunotherapy and radiotherapy demonstrates improved clinical outcomes in R/M HNSCC.https://doi.org/10.1007/s12672-025-02801-yImmune checkpoint inhibitorsRadiotherapyChemotherapyRecurrent/metastatic head and neck squamous cell carcinomaClinical outcome |
| spellingShingle | Yanshuang Cheng Juan Wang Ji Sun Yahua Zhong Qiuji Wu Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy Discover Oncology Immune checkpoint inhibitors Radiotherapy Chemotherapy Recurrent/metastatic head and neck squamous cell carcinoma Clinical outcome |
| title | Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| title_full | Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| title_fullStr | Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| title_full_unstemmed | Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| title_short | Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| title_sort | radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy |
| topic | Immune checkpoint inhibitors Radiotherapy Chemotherapy Recurrent/metastatic head and neck squamous cell carcinoma Clinical outcome |
| url | https://doi.org/10.1007/s12672-025-02801-y |
| work_keys_str_mv | AT yanshuangcheng radiotherapyimprovestheclinicaloutcomesofrecurrentormetastaticheadandneckcancerstreatedwithimmunotherapy AT juanwang radiotherapyimprovestheclinicaloutcomesofrecurrentormetastaticheadandneckcancerstreatedwithimmunotherapy AT jisun radiotherapyimprovestheclinicaloutcomesofrecurrentormetastaticheadandneckcancerstreatedwithimmunotherapy AT yahuazhong radiotherapyimprovestheclinicaloutcomesofrecurrentormetastaticheadandneckcancerstreatedwithimmunotherapy AT qiujiwu radiotherapyimprovestheclinicaloutcomesofrecurrentormetastaticheadandneckcancerstreatedwithimmunotherapy |